950 F.3d 134
1st Cir.2020Background
- Plaintiffs (relators) James Banigan and Richard Templin, former Organon employees, brought a qui tam action under the False Claims Act (FCA) alleging PharMerica participated in an Organon “Medicaid scheme” that used discounts/rebates and therapeutic interchange to induce pharmacies to convert or switch prescriptions to Organon’s Remeron products in violation of the Anti‑Kickback Statute (AKS), causing false Medicaid claims.
- Organon’s contracts (1999–2005) with long‑term care pharmacies (including PharMerica) included ramp‑up discounts, market‑share rebates, conversion rebates and therapeutic‑interchange bonuses designed to increase Remeron market share; some incentives transitioned from upfront discounts to post‑purchase rebates to avoid invoice disclosure.
- Banigan learned of the scheme from internal Organon emails and conversations with architects Maddox and McKenna, then independently obtained marketing materials and contracts corroborating the incentives; Templin learned of the program later and worked with Banigan.
- An earlier qui tam by LaCorte (Amerisource), filed in 2002, alleged PharMerica accepted kickbacks and listed Remeron among preferred drugs; that action settled and was dismissed in 2008.
- The district court dismissed the relators’ FCA claims under the public disclosure bar, finding the Amerisource disclosure substantially similar, and held neither relator qualified as an “original source.” The relators appealed.
- The First Circuit affirmed that the public disclosure bar applies but reversed dismissal because Banigan qualifies as an original source (direct and independent knowledge); Templin must be dismissed as a relator. Case remanded for further proceedings.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether the public‑disclosure bar bars the relators’ FCA suit | Banigan/Templin: their claims are not "based upon" Amerisource because they allege distinct conduct (switching vs conversion), broader time period, and more detail | PharMerica: relators’ complaint targets same Medicaid scheme disclosed in Amerisource; allegations are substantially similar so bar applies | Public‑disclosure bar applies — relators’ allegations target the same scheme disclosed in Amerisource |
| Whether relator(s) qualify as an "original source" (direct & independent knowledge) | Banigan: learned from Maddox/McKenna emails and conversations, then obtained internal marketing materials and contracts; thus has direct and independent knowledge | PharMerica: Banigan lacked direct knowledge because he neither participated in nor observed the fraud, learned late, and corroborating docs were obtained after scheme ended | Banigan qualifies as original source (direct = immediate); Templin does not qualify and must be dismissed as relator |
| Whether "direct" knowledge requires participation, contemporaneous observation, or discovery in ordinary course of duties | Banigan: statute does not require participation or contemporaneousness; corporate insiders who obtain immediate knowledge and corroborating documents qualify | PharMerica: courts should limit "direct" to participants/witnesses or contemporaneous knowledge to avoid secondhand informants | Court rejects strict participation/contemporaneity requirement; "direct" means knowledge without intervening agency — corporate insider knowledge here suffices |
| Remedy / disposition | Relators: original‑source exception preserves jurisdiction and case should proceed against PharMerica | PharMerica: public‑disclosure bar mandates dismissal of FCA claims | Court reverses district court dismissal as to FCA claims based on Banigan's original‑source status; remands for further proceedings; Templin dismissed as relator |
Key Cases Cited
- United States ex rel. Poteet v. Bahler Med., Inc., 619 F.3d 104 (1st Cir. 2010) (overview of FCA public‑disclosure concept)
- United States ex rel. Ondis v. City of Woonsocket, 587 F.3d 49 (1st Cir. 2009) (defines "based upon" as "substantially similar" and discusses "direct" knowledge)
- United States ex rel. Winkelman v. CVS Caremark Corp., 827 F.3d 201 (1st Cir. 2016) (greater detail in later complaint does not avoid public‑disclosure bar)
- Rockwell Int'l Corp. v. United States, 549 U.S. 457 (2007) (allegations in amended complaints count for public‑disclosure analysis)
- Kellogg Brown & Root Servs., Inc. v. United States ex rel. Carter, 575 U.S. 650 (2015) (first‑to‑file bar ceases to apply once earlier suit is dismissed)
- United States ex rel. Duxbury v. Ortho Biotech Prods., L.P., 579 F.3d 13 (1st Cir. 2009) (rejects overly restrictive reading of original‑source exception)
- United States ex rel. Saldivar v. Fresenius Med. Care Holdings, Inc., 841 F.3d 927 (11th Cir. 2016) (holding that being told by another department is generally not direct knowledge)